Truist Securities Maintains Buy on Immunovant, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has reaffirmed a Buy rating on Immunovant (NASDAQ:IMVT) and increased the price target from $30 to $48.
November 15, 2023 | 4:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunovant's stock may experience positive short-term movement due to the raised price target from $30 to $48 by Truist Securities, indicating strong confidence in the company's prospects.
Analyst upgrades typically lead to short-term positive sentiment among investors, as they often signal expectations of future growth or financial performance improvements. The substantial increase in the price target for Immunovant suggests a strong conviction in the company's potential, which could lead to increased investor interest and a rise in stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100